Glucagon-like peptide-1 regulates cholecystokinin production in β-cells to protect from apoptosis

Molecular Endocrinology

Volumn 29, Issue 7, 2015, Pages 978-987

  Linnemann, Amelia K ^a   Neuman, Joshua C ^b   Battiola, Therese J ^a   Wisinski, Jaclyn A ^a   Kimple, Michelle E ^a   Davis, Dawn Belt ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; TRANSCRIPTION FACTOR; INSULIN; PROTEIN BINDING;

ANIMAL CELL; APOPTOSIS; ARTICLE; BODY MASS; CELL PROTECTION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; INSULIN RELEASE; MOUSE; MUTATION; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; SECRETION (PROCESS); TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BODY MASS INDEX; CELL LINE, TUMOR; CHOLECYSTOKININ; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOPROTECTION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; MOLECULAR SEQUENCE DATA; OBESITY; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RATS; RECEPTORS, CHOLECYSTOKININ;

EID: 84936099734     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1030     Document Type: Article

References (42)

1. Linnemann AK, Baan M, Davis DB. Pancreatic β-cell proliferation in obesity. Adv Nutr. 2014;5(3):278–288.
2. Back SH, Kang S-W, Han J, Chung H-T. Endoplasmic reticulum stress in the β-cell pathogenesis of type 2 diabetes. Exp Diabetes Res. 2012;2012(5):1–11.
3. Liddle RA. Cholecystokinin cells. Annu Rev Physiol. 1997;59:221-242.
4. Ahrén B, Lundquist I. Effects of two cholecystokinin variants, CCK-39 and CCK-8, on basal and stimulated insulin secretion. Acta Diabetol Lat. 1981;18(4):345–356.
5. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev. 2006;86(3):805–847.
6. Woods SC, D’Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab. 2008;93(11 suppl 1):s37–s50.
7. Lan H, Rabaglia ME, Stoehr JP, et al. Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes. 2003;52(3):688-700.
8. Lavine JA, Raess PW, Stapleton DS, et al. Cholecystokinin is upregulated in obese mouse islets and expands β-cell mass by increasing β-cell survival. Endocrinology. 2010;151(8):3577–3588.
9. Deavall DG, Raychowdhury R, Dockray GJ, Dimaline R. Control of CCK gene transcription by PACAP in STC-1 cells. Am J Physiol Gastrointest Liver Physiol. 2000;279(3):G605–G612.
10. Hansen TV, Rehfeld JF, Nielsen FC. Mitogen-activated protein kinase and protein kinase A signaling pathways stimulate cholecystokinin transcription via activation of cyclic adenosine 3 β,5 β- monophosphate response element-binding protein. Mol Endocrinol. 1999;13(3):466–475.
11. Nielsen FC, Pedersen K, Hansen TV, Rourke IJ, Rehfeld JF. Transcriptional regulation of the human cholecystokinin gene: composite action of upstream stimulatory factor, Sp1, and members of the CREB/ATF-AP-1 family of transcription factors. DNA Cell Biol. 1996;15(1):53–63.
12. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3):153–165.
13. Lavine JA, Attie AD. Gastrointestinal hormones and the regulation of β-cell mass. Ann NY Acad Sci. 2010;1212(1):41–58.
14. Rabaglia ME, Gray-Keller MP, Frey BL, Shortreed MR, Smith LM, Attie AD. β-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice. Am J Physiol Endocrinol Metab. 2005;289(2):E218–E224.
15. Neuman JC, Truchan NA, Joseph JW, Kimple ME. A method for mouse pancreatic islet isolation and intracellular cAMP determination. J Vis Exp. 2014;(88):e50374.
16. Bhatnagar S, Oler AT, Rabaglia ME, et al. Positional cloning of a type 2 diabetes quantitative trait locus; tomosyn-2, a negative regulator of insulin secretion. PLoS Genet. 2011;7(10):e1002323.
17. Im H, Grass JA, Johnson KD, Boyer ME, Wu J, Bresnick EH. Measurement of protein-DNA interactions in vivo by chromatin immunoprecipitation. Methods Mol Biol. 2004;284:129–146.
18. Kilimnik G, Kim A, Steiner DF, Friedman TC, Hara M. Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α-cells in mouse models of β-cell regeneration. Islets. 2010;2(3):149–155.
19. Hansen AM, Bödvarsdottir TB, Nordestgaard DN, et al. Upregulation of α cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus—an adaptive response to hyperglycaemia? Diabetologia. 2011;54(6):1379–1387.
20. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and α cells. Nat Med. 2011;17(11):1481–1489.
21. Marchetti P, Lupi R, Bugliani, M et al. Alocal glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012; 55(12):3262–3272.
22. Ellingsgaard H, Ehses JA, Hammar EB, et al. Interleukin-6 regulates pancreatic α-cell mass expansion. Proc Natl Acad Sci USA. 2008;105(35):13163–13168.
23. Kimple ME, Keller MP, Rabaglia MR, et al. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013; 62(6):1904–1912.
24. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15–27.
25. Kimple ME, Joseph JW, Bailey CL, et al. Gαz negatively regulates insulin secretion and glucose clearance. J Biol Chem. 2008;283(8): 4560–4567.
26. Hahne WF, Jensen RT, Lemp GF, Gardner JD. Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. Proc Natl Acad Sci USA. 1981;78(10):6304–6308.
27. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952–957.
28. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide- 1-(7–36)amide is transformed to glucagon-like peptide-1-(9– 36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140(11): 5356–5363.
29. Donath MY, Burcelin R. GLP-1 Effects on islets: hormonal, neuronal, or paracrine? Diabetes Care. 2013;36(suppl 2):S145–S148.
30. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013; 56(5):965–972.
31. Wadden D, Cahill F, Amini P, et al. Circulating glucagon-like peptide- 1 increases in response to short-term overfeeding in men. Nutr Metab (Lond). 2013;10(1):33.
32. Irwin N, Montgomery IA, Moffett RC, Flatt PR. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice. Biochem Pharmacol. 2013;85(1):81–91.
33. Wang Y, Chandra R, Samsa LA, et al. Amino acids stimulate cholecystokinin release through the Ca2+-sensing receptor. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G528–G537.
34. Chandra R, Wang Y, Shahid RA, Vigna SR, Freedman NJ, Liddle RA. Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion. J Clin Invest. 2013; 123(8):3343–3352.
35. Vasu S, Moffett RC, Thorens B, Flatt PR. Role of endogenous GLP-1 and GIP in β cell compensatory responses to insulin resistance and cellular stress. PLoS One. 2014;9(6):e101005.
36. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired β-cell function. Hum Mol Genet. 2009;18(13): 2388–2399.
37. Flamez D, Gilon P, Moens K, et al. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes. 1999;48(10):1979–1986.
38. Li Y. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem. 2003;278(1):471–478.
39. Shin S, Le Lay J, Everett LJ, Gupta R, Rafiq K, Kaestner KH. CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse β -cells. Mol Metab. 2014;3(8):803–812.
40. Smith EP, An Z, Wagner C, et al. The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 2014;19(6):1050–1057.
41. Dor Y, Glaser B. β-Cell dedifferentiation and type 2 diabetes. N Engl J Med. 2013;368(6):572–573.
42. Irwin N, Hunter K, Montgomery IA, Flatt PR. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Diabetes Obes Metab. 2013;15(7):650–659.